Research
Hormonal
Dual GIP/GLP-1 agonism (tirzepatide) offers cardiovascular safety comparable to or better than insulin glargine, with no increased risk of major adverse cardiovascular events (MACE).
For patients with Type 2 Diabetes and heart disease concerns, tirzepatide has been shown to be cardiovascularly safe, with no increased risk of heart attacks or strokes compared to insulin glargine. This makes it a viable option for those prioritizing heart health alongside glucose control.
GoodSupportsHIGH confidence
Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants and were not increased on tirzepatide compared with glargine (hazard ratio: 0.74; 95% confidence interval: 0.51–1.08)
Why this rating
Based on Phase III trial data (SURPASS 4) and meta-analysis, but dedicated CVOT results were pending at publication.
Source
Next Step in Incretin-Based Therapy: From Single to Dual Agonism
Subhodip Pramanik et al. · EMJ Diabetes · 2022
DOI 10.33590/emjdiabet/22-00140
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →